Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) just unveiled an update.
GenFleet Therapeutics announced the full exercise of its over-allotment option, resulting in the issuance of 13,386,000 H Shares at HK$20.39 per share, which represents 15% of the total offer shares available under the Global Offering. The stabilization period for the Global Offering has ended, and the approval for listing these shares on the Hong Kong Stock Exchange has been granted, with trading expected to commence on October 21, 2025. This development is significant as it enhances the company’s financial standing and market presence, potentially benefiting stakeholders and solidifying its position in the biotechnology sector.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development and commercialization of innovative therapeutic products, primarily targeting the global market.
Average Trading Volume: 3,652,756
For detailed information about 2595 stock, go to TipRanks’ Stock Analysis page.